A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 30 May 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Apr 2024 Results (n=185) assessing efficacy and safety profile of ozanimod over 1 year were presented at the 76th Annual Meeting of the American Academy of Neurology 2024.
18 Apr 2024 Results presented at the 76th Annual Meeting of the American Academy of Neurology 2024
02 Mar 2024 Results of an ad hoc interim analysis (n= 185) assessing patient-reported outcomes (PROs) after 1 y of ozanimod, presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2024

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com